Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2014

01-11-2014 | Editorial

Iatrogenic/post-surgical hypoparathyroidism: where do we go from here?

Author: Saba P. Balasubramanian

Published in: Endocrine | Issue 2/2014

Login to get access

Excerpt

Hypoparathyroidism and hypocalcaemia have been described as postoperative complications since the early descriptions of thyroid surgery from the days of Kocher and Bilroth [1]. In addition, surgical hypoparathyroidism also occurs in a significant proportion of patients undergoing other surgical procedures such as parathyroidectomy [2] and laryngectomy [3]. The steady stream of publications on post-surgical hypoparathyroidism suggests that the problem is still of major significance to patients and surgeons. …
Literature
1.
R.B. Welbourn, The history of endocrine surgery (Praeger Publishers, New York, 1990)
2.
A. Bergenfelz, S. Jansson, H. Martensson, E. Reihner, G. Wallin, A. Kristoffersson, I. Lausen, Scandinavian Quality Register for Thyroid and Parathyroid Surgery: audit of surgery for primary hyperparathyroidism. Langenbecks Arch. Surg. 392(4), 445–451 (2007). doi:10.​1007/​s00423-006-0097-6 PubMedCrossRef
3.
4.
M.R. Pelizzo, M. Variolo, C. Bernardi, M. Izuzquiza, A. Piotto, G. Grassetto, P.M. Colletti, I. Merante Boschin, D. Rubello, Complications in thyroid resurgery: a single institutional experience on 233 patients from a whole series of 4,752 homogeneously treated patients. Endocrine (2014). doi:10.​1007/​s12020-014-0225-y
5.
D.R. Chadwick, R. Kinsman: The British Association of Endocrine and Thyroid Surgeons. ed. by D.R. Chadwick 4th National Audit Report, (British Association fo Endocrine and Thyroid Surgeons, Henley-on-Thames, 2012), p. 1–184
6.
A. Puzziello, L. Rosato, N. Innaro, G. Orlando, N. Avenia, G. Perigli, P.G. Calo, M. De Palma, Hypocalcemia following thyroid surgery: incidence and risk factors. A longitudinal multicenter study comprising 2,631 patients. Endocrine (2014). doi:10.​1007/​s12020-014-0209-y PubMed
7.
A. Bergenfelz, S. Jansson, A. Kristoffersson, H. Martensson, E. Reihner, G. Wallin, I. Lausen, Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. Langenbecks Arch. Surg. 393(5), 667–673 (2008). doi:10.​1007/​s00423-008-0366-7 PubMedCrossRef
8.
H.M. Mehanna, A. Jain, H. Randeva, J. Watkinson, A. Shaha, Postoperative hypocalcemia–the difference a definition makes. Head Neck 32(3), 279–283 (2010). doi:10.​1002/​hed.​21175 PubMed
9.
T.C. Dembinski, R.W. Yatscoff, D.E. Blandford, Thyrotoxicosis and hungry bone syndrome–a cause of posttreatment hypocalcemia. Clin. Biochem. 27(1), 69–74 (1994)PubMedCrossRef
10.
O. Edafe, R. Antakia, N. Laskar, L. Uttley, S.P. Balasubramanian, Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. Br. J. Surg. (2014). doi:10.​1002/​bjs.​9384
11.
R. Antakia, P. Gayet, S. Guillermet, T.J. Stephenson, N.J. Brown, B.J. Harrison, S.P. Balasubramanian, Near infrared fluorescence imaging of rabbit thyroid and parathyroid glands. J. Surg. Res. (2014). doi:10.​1016/​j.​jss.​2014.​05.​061 PubMed
12.
S. Takeuchi, K. Shimizu, K. Shimizu Jr, H. Akasu, R. Okamura, Identification of pathological and normal parathyroid tissue by fluorescent labeling with 5-aminolevulinic acid during endocrine neck surgery. J. Nippon Med. Sch. 81(2), 84–93 (2014)PubMedCrossRef
13.
W.M. White, G.J. Tearney, B.Z. Pilch, R.L. Fabian, R.R. Anderson, R.D. Gaz, A novel, noninvasive imaging technique for intraoperative assessment of parathyroid glands: confocal reflectance microscopy. Surgery 128(6), 1088–1100 (2000). doi:10.​1067/​msy.​2000.​111190. discussion 1100-1081PubMedCrossRef
14.
R. Ladurner, K.K. Hallfeldt, N. Al Arabi, H. Stepp, S. Mueller, J.K. Gallwas, Optical coherence tomography as a method to identify parathyroid glands. Lasers. Surg. Med. 45(10), 654–659 (2013). doi:10.​1002/​lsm.​22195 PubMedCrossRef
15.
A. Sitges-Serra, S. Ruiz, M. Girvent, H. Manjon, J.P. Duenas, J.J. Sancho, Outcome of protracted hypoparathyroidism after total thyroidectomy. Br. J. Surg. 97(11), 1687–1695 (2010). doi:10.​1002/​bjs.​7219 PubMedCrossRef
16.
N.L. Cho, J. Moalem, L. Chen, C.C. Lubitz, F.D. Moore, D.T. Ruan, Surgeons and patients disagree on the potential consequences from hypoparathyroidism. Endocr. Pract. 20(5), 427–446 (2014). doi:10.​4158/​EP13321.​OR PubMedCrossRef
17.
18.
19.
L. Underbjerg, T. Sikjaer, L. Mosekilde, L. Rejnmark, Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J. Bone. Miner. Res. 28(11), 2277–2285 (2013). doi:10.​1002/​jbmr.​1979 PubMedCrossRef
20.
L. Underbjerg, T. Sikjaer, L. Mosekilde, L. Rejnmark, Post-Surgical Hypoparathyroidism - Risk of Fractures, Psychiatric Diseases, Cancer, Cataract, and Infections. J. Bone. Miner. Res. (2014). doi:10.​1002/​jbmr.​2273 PubMed
21.
22.
23.
K.K. Winer, C.W. Ko, J.C. Reynolds, K. Dowdy, M. Keil, D. Peterson, L.H. Gerber, C. McGarvey, G.B. Cutler Jr, Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1–34) versus calcitriol and calcium. J. Clin. Endocrinol. Metab. 88(9), 4214–4220 (2003). doi:10.​1210/​jc.​2002-021736 PubMedCrossRef
24.
N.E. Cusano, M.R. Rubin, D.J. McMahon, D. Irani, L. Anderson, E. Levy, J. Bilezikian, PPTH(1–84) Is Associated with Improved Quality of Life in Hypoparathyroidism Through 5 Years of Therapy. J. Clin. Endocrinol. Metab. (2014). doi:10.​1210/​jc.​2014-2267
Metadata
Title
Iatrogenic/post-surgical hypoparathyroidism: where do we go from here?
Author
Saba P. Balasubramanian
Publication date
01-11-2014
Publisher
Springer US
Published in
Endocrine / Issue 2/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0397-5

Other articles of this Issue 2/2014

Endocrine 2/2014 Go to the issue

Editorial

Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect

Original Article

Detection of serum p53 antibodies from Chinese patients with papillary thyroid carcinoma using phage-SP-ELISA: correlation with clinical parameters

Original Article

Contribution of protein kinase Cα in the stimulation of insulin by the down-regulation of Cavβ subunits

Original Article

The associations between cardiometabolic risk factors and visceral fat measured by a new dual-energy X-ray absorptiometry-derived method in lean healthy Caucasian women

Original Article

Sustained high levels of serum leptin rather than IL-6 observed in patients with postpartum thyroiditis during their first postpartum year

Review

STEAP4 and insulin resistance
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits